What Has Been the Progress and Growth of the Minimally Invasive Glaucoma Surgery (MIGS) Devices Market in Recent Years?
The minimally invasive glaucoma surgery (migs) devices market has seen considerable growth due to a variety of factors.
• The minimally invasive glaucoma surgery (MIGS) devices market has experienced exponential growth in recent years. It will rise from $0.7 billion in 2024 to $0.9 billion in 2025, reflecting a CAGR of 28.3%.
This growth is attributed to heightened awareness about blindness prevention, increased investments in healthcare infrastructure, growing patient awareness of advanced vision treatments, and government initiatives.
What Can Be Expected from the Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Size?
The minimally invasive glaucoma surgery (migs) devices market is expected to maintain its strong growth trajectory in upcoming years.
• The minimally invasive glaucoma surgery (MIGS) devices market is expected to grow exponentially, reaching $2.42 billion by 2029 at a CAGR of 28.1%.
Growth is driven by the increasing prevalence of glaucoma, an aging population, better healthcare infrastructure, and the demand for safer treatments. Trends include MIGS device adoption, technological advancements, innovative device development, and improvements in ophthalmic surgery techniques.
What Are the Critical Driver Fuelling The Minimally Invasive Glaucoma Surgery (MIGS) Devices Market's Growth?
The rising prevalence of eye disorders is expected to drive the growth of minimally invasive glaucoma surgery (MIGS) devices. Eye disorders include a variety of conditions that impact vision and eye health. The increase in these conditions is attributed to lifestyle changes, environmental factors, and aging populations. MIGS devices are used to manage eye diseases, particularly glaucoma, by lowering intraocular pressure (IOP). For example, in 2024, the National Eye Institute predicted that by 2030, 2.2 million Americans would be blind or partially blind. Thus, the growing prevalence of eye disorders is propelling the MIGS devices market.
How Is The Minimally Invasive Glaucoma Surgery (MIGS) Devices Market segmented?
The minimally invasive glaucoma surgery (MIGS) devices market covered in this report is segmented –
1) By Product: Valves, Glaucoma Drainage Implant, Glaucoma Tube Shunts, Stents, Other Products
2) By Surgery: Glaucoma In Conjunction With Cataract, Stand Alone Glaucoma
3) By Target: Trabecular Meshwork, Suprachoroidal Space, Other Targets
4) By Distribution Channel: Direct Tender, Retail Sales
5) By End User: Ophthalmology Clinics, Ambulatory Surgery Centers (ASCS), Other End Users
Subsegments:
1) By Valves: Micro Shunt Valves, Non-penetrating Valves
2) By Glaucoma Drainage Implant: Scleral Drainage Implants, Subconjunctival Drainage Implants
3) By Glaucoma Tube Shunts: Ahmed Tube Shunt, Baerveldt Tube Shunt
4) By Stents: Ab-Interno Stents, Ab-Externo Stents
5) By Other Products: Cyclodestructive Devices, Trabecular Bypass Devices
Pre-Book The Minimally Invasive Glaucoma Surgery (MIGS) Devices Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Shaping The Minimally Invasive Glaucoma Surgery (MIGS) Devices Market?
Leading firms in the minimally invasive glaucoma surgery (MIGS) devices market are prioritizing the creation of novel products such as stent injectable systems. These developments aim to meet the unsolved issues in managing glaucoma and enhance patient results. A stent injectable system is a MIGS tool that utilizes an injection-like process to deliver and implant a small stent into the patient's body using a specialized delivery mechanism commonly employed in minimally invasive procedures for diseases like obstructed or narrowed blood vessels. For example, in August 2022, Glaukos Corporation, an American ophthalmic medical technology firm, was granted 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the iStent Infinite Trabecular Micro-Bypass System. This novel three-stent injectable system, the iStent Infinite, is designed to provide a foundational, round-the-clock intraocular pressure (IOP) control for patients with primary open-angle glaucoma (POAG) who are not responding well to previous medication and surgical therapy.
Who Are the Key Players In The Minimally Invasive Glaucoma Surgery (MIGS) Devices Market?
Major companies operating in the minimally invasive glaucoma surgery (MIGS) devices market are:
• AbbVie Inc.
• Novartis AG
• Alcon Inc.
• Bausch Health Companies Inc.
• Bausch & Lomb Incorporated Inc.
• Carl Zeiss Meditec AG
• Santen Pharmaceutical Co. Ltd.
• Johnson & Johnson Vision Care Inc.
• Lumenis Ltd.
• Staar Surgical Company
• Glaukos Corporation
• Sight Sciences Inc.
• Ocular Therapeutix Inc.
• Iridex Corporation
• Ellex Medical Lasers Ltd.
• New World Medical Inc.
• MicroSurgical Technology Inc.
• Nova Eye Medical Limited
• Asico LLC
• Ziemer Ophthalmic Systems AG
• Transcend Medical
• iSTAR Medical SA
• Ivantis Group Inc.
• Allergan
• InnFocus Inc.
What Is The Most Dominant Region In The Minimally Invasive Glaucoma Surgery (MIGS) Devices Market?
North America was the largest region in the minimally invasive glaucoma surgery (MIGS) devices market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the minimally invasive glaucoma surgery (MIGS) devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
